RAPT Therapeutics’ (RAPT) Neutral Rating Reiterated at HC Wainwright

HC Wainwright restated their neutral rating on shares of RAPT Therapeutics (NASDAQ:RAPT) in a research report sent to investors on Monday,Benzinga reports. HC Wainwright also issued estimates for RAPT Therapeutics’ Q4 2024 earnings at ($0.58) EPS, FY2024 earnings at ($2.56) EPS, Q2 2025 earnings at ($0.66) EPS, Q3 2025 earnings at ($0.69) EPS, Q4 2025 earnings at ($0.63) EPS and FY2025 earnings at ($2.61) EPS.

Several other research analysts have also issued reports on RAPT. Piper Sandler lowered RAPT Therapeutics from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $8.00 to $2.00 in a research report on Monday, November 11th. JPMorgan Chase & Co. downgraded RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a research report on Monday, November 11th. Stifel Nicolaus reiterated a “hold” rating and issued a $2.00 target price (down from $7.00) on shares of RAPT Therapeutics in a report on Wednesday, November 13th. Wells Fargo & Company lowered their price target on shares of RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a report on Tuesday, November 12th. Finally, UBS Group dropped their price target on shares of RAPT Therapeutics from $10.00 to $2.00 and set a “neutral” rating on the stock in a research report on Monday, September 9th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and two have issued a buy rating to the stock. According to MarketBeat, RAPT Therapeutics has an average rating of “Hold” and an average price target of $9.50.

RAPT Therapeutics Trading Up 9.8 %

NASDAQ:RAPT opened at $1.23 on Monday. The stock has a 50 day simple moving average of $1.80 and a 200 day simple moving average of $2.61. The stock has a market cap of $43.00 million, a P/E ratio of -0.44 and a beta of 0.33. RAPT Therapeutics has a 1-year low of $1.00 and a 1-year high of $27.35.

RAPT Therapeutics (NASDAQ:RAPT) last issued its earnings results on Tuesday, November 12th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.09. As a group, sell-side analysts forecast that RAPT Therapeutics will post -2.73 EPS for the current year.

Institutional Trading of RAPT Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. increased its holdings in shares of RAPT Therapeutics by 21.2% in the 1st quarter. Vanguard Group Inc. now owns 2,492,850 shares of the company’s stock worth $22,386,000 after purchasing an additional 436,629 shares in the last quarter. Point72 Asset Management L.P. increased its holdings in RAPT Therapeutics by 176,725.0% in the 2nd quarter. Point72 Asset Management L.P. now owns 707,300 shares of the company’s stock worth $2,157,000 after buying an additional 706,900 shares in the last quarter. Cubist Systematic Strategies LLC raised its position in RAPT Therapeutics by 826.4% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 295,241 shares of the company’s stock worth $900,000 after buying an additional 263,372 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in shares of RAPT Therapeutics by 4,183.3% during the 2nd quarter. Acadian Asset Management LLC now owns 467,182 shares of the company’s stock valued at $1,424,000 after acquiring an additional 456,275 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of RAPT Therapeutics in the second quarter worth approximately $108,000. 99.09% of the stock is owned by hedge funds and other institutional investors.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.